Daily Archives: 2012/06/12
Vision Trouble in Preemies Tied to Brain Damage (CME/CE)
(MedPage Today) -- A global developmental deficit -- an indicator of cerebral damage -- may be the primary risk factor for visual impairment in children born extremely premature, a Danish study showed.
Genetic Testing For Color Vision Makes Commercial Debut for Military Applications
Possibly heralding a new era in the use of genetic testing for hiring decisions, Genevolve (Albuquerque, NM) announced at the recent Aerospace Medicine Association conference in Atlanta, GA a new “military grade” test for inherited color blindness. A few years ago we posted on research done at the Neitz lab at the University of Washingt (Read more...)
Review: Comparative effectiveness of anti-growth factor therapies for diabetic macular oedema
Source: Arch Internal Med
Area: News
This review outlines the clinical effectiveness and potential harms of off-label intravitreal administration of anti-VEGF drugs (pegaptanib, bevacizumab, ranibizumab, and aflibercept) for diabetic macular oedema.
Area: News
This review outlines the clinical effectiveness and potential harms of off-label intravitreal administration of anti-VEGF drugs (pegaptanib, bevacizumab, ranibizumab, and aflibercept) for diabetic macular oedema.
Retrospective study: Risk of macular oedema among patients with type 2 diabetes treated with thiazolidinedione
Source: Arch Internal Med
Area: News
This retrospective study, using The Health Improvement Network (THIN) database, evaluated the short and long-term risks of developing diabetic macular oedema (DMO) among patients with type 2 diabetes who were treated with thiazolidinediones (rosiglitazone and pioglitazone). Researchers identified adult patients with type 2 diabetes (not requiring insulin therapy within 6 months of diagnosis), were 18 years or older, and were registered with the medical practices for at least one year from the index date of January 2000. The THIN database also determined the use of prescribed thiazolidinediones prior to the diagnosis of DMO or prior to censuring of patients with no diagnosis of DME. The primary outcome measure of the study was a new diagnosis of DMO as indicated by READ codes. The following results were reported: . A total of 103,368 patients met the inclusion criteria. . At 1 year, the incidence of DMO was 1.3% (n = ...
Area: News
This retrospective study, using The Health Improvement Network (THIN) database, evaluated the short and long-term risks of developing diabetic macular oedema (DMO) among patients with type 2 diabetes who were treated with thiazolidinediones (rosiglitazone and pioglitazone). Researchers identified adult patients with type 2 diabetes (not requiring insulin therapy within 6 months of diagnosis), were 18 years or older, and were registered with the medical practices for at least one year from the index date of January 2000. The THIN database also determined the use of prescribed thiazolidinediones prior to the diagnosis of DMO or prior to censuring of patients with no diagnosis of DME. The primary outcome measure of the study was a new diagnosis of DMO as indicated by READ codes. The following results were reported: . A total of 103,368 patients met the inclusion criteria. . At 1 year, the incidence of DMO was 1.3% (n = ...
System Boosts Glaucoma Compliance (CME/CE)
(MedPage Today) -- An automated and interactive program of telephone calls improved adherence to glaucoma treatment in a randomized trial but so did usual care, researchers reported.
SMC accepts restricted use of dexamethasone intravitreal implant (Ozurdex®) for macular oedema following branch retinal vein occlusion or central retinal vein occlusion
Source: Scottish Medicines Consortium (SMC)
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) has accepted dexamethasone intravitreal implant (Ozurdex®) for restricted use within NHS Scotland for the treatment of adult patients with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. The SMC states that it is restricted for use in adults with macular oedema: . following central retinal vein occlusion (CRVO) and . in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment. Please see link below for details.
Area: Evidence > Drug Specific Reviews
The Scottish Medicines Consortium (SMC) has accepted dexamethasone intravitreal implant (Ozurdex®) for restricted use within NHS Scotland for the treatment of adult patients with macular oedema following either branch retinal vein occlusion or central retinal vein occlusion. The SMC states that it is restricted for use in adults with macular oedema: . following central retinal vein occlusion (CRVO) and . in patients with branch retinal vein occlusion (BRVO) who are not clinically suitable for laser treatment including patients with dense macular haemorrhage or patients who have received and failed on previous laser treatment. Please see link below for details.
RVO advances PresbyLens into final phase of trial for treatment of presbyopia
ReVision Optics, Inc. (RVO), a leader in implantable inlay technology to treat presbyopia, announces the advancement of its proprietary product PresbyLens into the final phase of its U.S. clinical trial under an Investigational Device Exemption
Thiazolidinediones: Do They Increase Risk for Macular Edema?
A large retrospective study suggests that patients with type 2 diabetes mellitus who take thiazolidinediones are at increased risk for macular edema, but other experts say more data are needed.
Medscape Medical News
Medscape Medical News
Avandia, Actos May Raise Risk of Macular Edema (CME/CE)
(MedPage Today) -- The diabetes drugs pioglitazone (Actos) and rosiglitazone (Avandia) appear to substantially boost the risk of macular edema in type 2 disease, an observational study found.
Subscribe
